Recent 8-K filings for BCAX
Highest-materiality recent filing
Bicara reports 31% 3-year OS with ficerafusp alfa + pembro in 1L R/M HPV-negative HNSCC
- Ficerafusp alfa 1500mg QW + pembrolizumab showed estimated 31% OS at 3 years, ~double retrospective standard of care OS (Vasiliadou et al. 2024).
- CR rates matured to 13%, 25%, 30% across 750mg QW, 1500mg QW, 2000mg Q2W cohorts; deep responses (≥80% shrinkage) in 80% and 77% at higher doses.
-
Bicara reports 31% 3-year OS with ficerafusp alfa + pembro in 1L R/M HPV-negative HNSCC
Ficerafusp alfa 1500mg QW + pembrolizumab showed estimated 31% OS at 3 years, ~double retrospective standard of care OS (Vasiliadou et al. 2024).
-
Bicara Q1 net loss $56.2M; cash $539.8M; appoints new CMO and CCO; advances ficerafusp alfa
Net loss of $56.2M for Q1 2026 vs $36.8M YoY; R&D expenses $47.5M, G&A $12.7M.
-
Bicara reports FY2025 net loss $138M; cash $414.8M; raises $161.8M in public offering
Net loss Q4 2025 $37.4M, full year $138.0M vs $21.0M and $68.0M in 2024.
-
Bicara raises $161.8M in public offering; reports preliminary cash of $414.8M
Net proceeds of ~$161.8M from offering of 7.175M shares at $16.00/sh and 2.2M pre-funded warrants.
-
Bicara Phase 1b data: ficerafusp alfa 2000mg Q2W shows 48% ORR, 26% CR in 1L HPV-negative HNSCC
48% confirmed ORR and 26% complete response rate in 27 patients with 1L HPV-negative R/M HNSCC.
-
Bicara selects 1500 mg ficerafusp alfa dose for Phase 3 pivotal HNSCC study
Selected 1500 mg QW ficerafusp alfa plus pembrolizumab as optimal dose for Phase 3 FORTIFI-HN01 in 1L HPV-negative R/M HNSCC.
-
750mg ficerafusp alfa + pembrolizumab showed 57% confirmed ORR (17/30) with 10% complete response.
-
Net loss $36.3M in Q3 2025 vs $17.5M in Q3 2024; R&D expenses rose to $33.0M from $15.9M.
-
Bicara Therapeutics Q2 2025: Cash $436.6M, net loss $27.4M; Phase 1/1b data show 54% ORR in HNSCC
Cash and equivalents $436.6M as of Jun 30, 2025, expected to fund operations into H1 2029.
-
Bicara Therapeutics shareholders elect three Class I directors, ratify KPMG
Elected Kiran Mazumdar-Shaw, Jake Simson, and Ryan Cohlhepp as Class I directors for three-year terms.
-
Bicara Therapeutics subleases 9,682 sq ft of HQ office space through June 2027
Sublease covers approx. 9,682 sq ft at 116 Huntington Ave, Boston, MA.
-
Bicara Therapeutics Q1 net loss $36.8M; cash $462M; ASCO data update planned
Cash and cash equivalents of $462.1M as of March 31, 2025, expected to fund operations into H1 2029.
-
Bicara Therapeutics reports Q4 net loss $21M, cash $489.7M; pivotal Phase 2/3 trial dosing started
Net loss $21.0M in Q4 2024, $68.0M full year; vs $12.4M and $52.0M in 2023.
-
Bicara Therapeutics furnishes corporate presentation, no new material disclosures
Presentation is a general corporate overview; no financial results or guidance provided.
-
Bicara Therapeutics Q3 net loss $17.5M; cash $520.8M; pivotal HNSCC trial on track
Cash and cash equivalents $520.8M as of Sep 30, 2024, funding operations into H1 2029.
-
Bicara Therapeutics files amended charter and bylaws post-IPO, increases authorized shares to 500M
Authorized 500 million shares of common stock and 10 million shares of undesignated preferred stock.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.65 · Most common event other_material